Market Overview

UPDATE: Canaccord Genuity Reduces PT to $59 on Quest Diagnostics


Canaccord Genuity reiterated its Hold rating on Quest Diagnostics (NYSE: DGX) and reduced its price target from $60 to $59.

Canaccord Genuity noted, "We reiterate our HOLD following soft 3Q results. Utilization, pricing, and share shift from labs to hospitals remain significant pressures, causing a lower 2012 outlook. While we appreciate the acceleration of the cost- cutting and debt repayment, we remain on the sidelines. … Lowering our 2012E revenue growth rate to 0.4% from 1.5% and our EPS estimate to $4.55 from $4.58. For 2013, we lowered our revenue growth to 0.5% from 2.1% and our EPS estimate to $4.90 from $4.95, lowering our PT to $59 from $60."

Quest Diagnostics closed at $63.37 on Tuesday.

Latest Ratings for DGX

Jul 2019DowngradesNeutralSell
Apr 2019MaintainsOverweightOverweight
Apr 2019MaintainsNeutral

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (DGX)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Are Financials Pricing in a Romney Win?

UPDATE: JP Morgan Reduces PT to $65 on Newmont Mining on Production Update